Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H1 2018

April 2018 | 64 pages | ID: VAB0EF67474EN
Global Markets Direct

Abstracts

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H1 2018

SUMMARY

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Vascular endothelial growth factor B also known as VEGF-B is a protein encoded by the VEGF-B gene. It regulates the formation of blood vessels and is involved in endothelial cell physiology. It is a ligand for VEGFR-1 (vascular endothelial growth factor receptor 1) and NRP-1 (neuropilin-1).

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) pipeline Target constitutes close to 8 molecules. The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 5 respectively. Report covers products from therapy areas Metabolic Disorders, Ophthalmology and Oncology which include indications Wet (Neovascular/Exudative) Macular Degeneration, Diabetic Macular Edema, Diabetic Nephropathy, Diabetic Retinopathy, Choroidal Neovascularization, Lipid Disorders, Neovascular Glaucoma, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy, Retinal Vein Occlusion and Retinopathy.

The latest report Vascular Endothelial Growth Factor B - Pipeline Review, H1 2018, outlays comprehensive information on the Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
• The report reviews Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics and enlists all their major and minor projects
• The report assesses Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Overview
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Companies Involved in Therapeutics Development
Alteogen Inc
Benitec Biopharma Ltd
CSL Ltd
Eli Lilly and Co
Formycon AG
Momenta Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Drug Profiles
(aflibercept + nesvacumab) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BB-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSL-346 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ziv-aflibercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Dormant Products
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Discontinued Products
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Product Development Milestones
Featured News & Press Releases
Mar 20, 2018: Aflibercept shows promising data for non-proliferative DR
Mar 19, 2018: EYLEA (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial
Feb 13, 2018: Bayer Receives First Approval for Eylea in China
Feb 12, 2018: New data for aflibercept show prolonged injection intervals
Jan 03, 2018: Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA (aflibercept)
Dec 21, 2017: Bayer Yakuhin Announces Results on EYLEA at the 11th Asia Pacific Retinal Vitreological Society (APVRS)
Dec 11, 2017: Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA (aflibercept) Injection for Patients with Wet AMD
Nov 27, 2017: Regeneron Provides Update on Eylea (Aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program
Sep 22, 2017: NICE gives EYLEA the Green Light for Treating Visual Impairment Due to mCNV
Aug 30, 2017: Bayer to showcase latest Ophthalmology research at EURETINA 2017
Jul 10, 2017: New use of drug could reduce need for laser treatment in diabetes
May 09, 2017: The first UK trial comparing intravitreal aflibercept and laser for proliferative diabetic retinopathy reports at ARVO 2017
Feb 10, 2017: Study Published in Cell Metabolism shows Potential New Therapy for Diabetic Kidney Disease
Feb 02, 2017: Benitec Biopharma makes significant progress in ocular program
Dec 01, 2016: CSL Commits to New Phase I Clinical Trials of CSL346 in Australia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Alteogen Inc, H1 2018
Pipeline by Benitec Biopharma Ltd, H1 2018
Pipeline by CSL Ltd, H1 2018
Pipeline by Eli Lilly and Co, H1 2018
Pipeline by Formycon AG, H1 2018
Pipeline by Momenta Pharmaceuticals Inc, H1 2018
Pipeline by Regeneron Pharmaceuticals Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Alteogen Inc
Benitec Biopharma Ltd
CSL Ltd
Eli Lilly and Co
Formycon AG
Momenta Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc